The drug pricing debate is top of mind with manufacturers, payers, governments, patients, and the medical professionals who treat them. In this issue of CRA Insights: Life Sciences we examine some of these issues.
Funding innovation under pressure: examining the role of commercial health insurance in Europe
Europe’s health systems are facing growing pressure amidst strained public budgets, ageing populations, and increasing treatment costs, prompting urgent questio